Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%
A personalized mRNA melanoma vaccine from Merck and Moderna showed a 49% reduction in cancer recurrence or death over five years when combined with immunotherap...
America Forever Bytes
Merck · AFBytes
Company
Merck
Recent coverage
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.